Scleromyxedema

Dinneen, Annette M.; Dicken, Charles H.

doi:10.1016/0190-9622(95)90007-1

Cited by 195 publications

(202 citation statements)

References 24 publications

Supporting

Mentioning

159

Contrasting

Unclassified

Order By: Relevance

“…1,2 The myxedematous lichen spectre (papular mucinosis) was originally described by Dubreuilh and Reitman, in 1906. 3 In 1953, Montgomery and Underwood 4 classified the myxedematous lichen into four clinical forms: (1) generalized lichenous papular eruption; (2) nonconfluent papular form; (3) localized or generalized lichenous plaques; and (4) urticaria-like plaques and nodular lichenous eruptions.…”

Section: Introductionmentioning

confidence: 99%

Escleromixedema: um caso tratado com prednisona oral

Neto

Sales

Silva

et al. 2006

An. Bras. Dermatol.

View full text Add to dashboard Cite

Scleromyxedema is an idiopathic cutaneous mucinosis characterized by a papular eruption, skin induration and paraproteinemia. Histologically, fibrolast proliferation can be observed in the upper dermis associated with a mucine deposition. Treatment is difficult and at present there is no totally effective therapeutic modality to control the disease. The present report is on a 68-year-old patient with scleromyxedema without systemic manifestation, who responded to oral steroid therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Escleromixedema: um caso tratado com prednisona oral

Neto

Sales

Silva

et al. 2006

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…Sistem sorgulamasında halsizlik, yorgunluk, ses kısıklığı mevcuttu. Hastanın ensesinden ve elinden eritema multiforme, Sweet 4,5 . Yüz bölgesinde deri kalınlaşması derin oluklar oluşturur ve tipik aslan yüz görünümüne neden olur.…”

Section: Olgu Sunumuunclassified

A case of angioedema-like atypic scleromyxedema responding to treatment with steroid

Polat¹,

Kapıcıoğlu²,

Şahin³

et al. 2016

TURKDERM

View full text Add to dashboard Cite

Lichen myxedematosus is a chronic, inflammatory, systemic dermatose characterized by dermal musin deposition and increased fibroblasts in the absence of thyroid dysfunction. It is usually seen together with paraproteinemia. It is clinically classified as scleromyxedema (papular mucinosis), localized lichen myxedematosus, and atypical lichen myxedematosus. Etiopathogenesis of the disease which is very difficult to treat is still unknown. Herein, we present a case of atypical scleromyxedema without monoclonal gammopathy mimicking angioedema, rapidly developing and responding to steroid treatment.

show abstract

“…1 It tends to have a chronic and progressive course, with a high mortality rate from extracutaneous involvements. 2 Response to alkylator-based chemotherapy or other therapies tends to be short. 2,3 Chronic oral lowdose melphalan is the most commonly used chemotherapy, but rarely results in durable remissions, and is associated with a 30% TRM rate.…”

mentioning

confidence: 99%

“…2 Response to alkylator-based chemotherapy or other therapies tends to be short. 2,3 Chronic oral lowdose melphalan is the most commonly used chemotherapy, but rarely results in durable remissions, and is associated with a 30% TRM rate. 2 A few reports suggest significant potential benefit of high-dose chemotherapy (HDCT) and auto-SCT for scleromyxedema patients.…”

mentioning

confidence: 99%

“…2,3 Chronic oral lowdose melphalan is the most commonly used chemotherapy, but rarely results in durable remissions, and is associated with a 30% TRM rate. 2 A few reports suggest significant potential benefit of high-dose chemotherapy (HDCT) and auto-SCT for scleromyxedema patients. [4][5][6][7][8] We report a case of life-threatening scleromyxedema, refractory to prior oral melphalan, but successfully treated with HD melphalan, BU and auto-SCT, with complete clinical remission at 5 years following treatment.…”

mentioning

confidence: 99%

See 1 more Smart Citation